
    
      Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at
      oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding
      decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood
      supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
    
  